Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?

① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.

cls.cn04:08 ET

HK stocks move | CRO Concept stocks' gains widen, WUXI BIO (02269) rises over 6%. The Industry leader's revenue and profit have stabilized and rebounded in the fourth quarter.

The gains of CRO Concept stocks have expanded. As of the time of writing, VIVA BIOTECH (01873) is up 6.19%, priced at 2.06 Hong Kong dollars; WUXI BIO (02269) is up 5.92%, priced at 27.75 Hong Kong dollars; Joinn Laboratories (06127) is up 5.3%, priced at 15.9 Hong Kong dollars; WUXI APPTEC (02359) is up 5.46%, priced at 70.55 Hong Kong dollars; PHARMARON (03759) is up 5.16%, priced at 16.72 Hong Kong dollars.

Zhitong Finance03:43 ET

Trending Industry Today: WUXI BIO Leads Gains In CRO Stocks

Moomoo News02:40 ET

Trending Industry Today: WUXI XDC Leads Gains In Biotechnology Stocks

Moomoo News02:20 ET

An Intrinsic Calculation For WuXi AppTec Co., Ltd. (SHSE:603259) Suggests It's 45% Undervalued

Simply Wall St01:47 ET

WUXI APPTEC (603259.SH, 02359) remains unyielding against adversity, crossing cycles for steady growth, a victory of resilient genes and long-termism.

In 2024, WUXI APPTEC achieved its performance guidance set at the beginning of the year. In 2025, under the dual narrative of "steady growth + shareholder returns," WUXI APPTEC is even more值得期待.

Zhitong FinanceMar 25 20:40 ET